A.R.T. Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

A.R.T. Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-16,387	Closed	-$394K	–	1915
2019 Q2	$394K	Sell	16,387 -25,800	-61%	-$654K	0.02%	841
2019 Q1	$1.11M	Sell	42,187 -20,400	-33%	-$483K	0.07%	441
2018 Q4	$1.22M	Buy	+62,587	New	+$1.23M	0.08%	376
2018 Q2	–	Sell	-80,336	Closed	-$1.14M	–	1954
2018 Q1	$1.14M	Buy	+80,336	New	+$1.19M	0.05%	601
2015 Q2	–	Sell	-83,829	Closed	-$2.18M	–	1835
2015 Q1	$2.18M	Sell	83,829 -5,405	-6%	-$99.1K	0.08%	368
2014 Q4	$1.15M	Sell	89,234 -81,962	-48%	-$1.03M	0.04%	588
2014 Q3	$2.1M	Buy	+171,196	New	+$1.99M	0.1%	291
2014 Q2	–	Sell	-55,093	Closed	-$833K	–	1648
2014 Q1	$833K	Sell	55,093 -58,656	-52%	-$662K	0.04%	563
2013 Q4	$866K	Buy	+113,749	New	+$613K	0.05%	532

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

A.R.T. Advisors's HZNP Position: Q3 2019 in Review

A.R.T. Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2019, closing a stake of 16,387 shares — an estimated $394K sold.

A.R.T. Advisors first reported a position in HZNP in Q4 2013 and held it in 9 quarters. The position peaked at $2.18M in Q1 2015. 264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

A.R.T. Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2019 after selling out during the quarter.
A.R.T. Advisors sold 16,387 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2019, an estimated $394K.
A.R.T. Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 9 quarters.
A.R.T. Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.18M in Q1 2015.
264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.